FDA decision on Tysabri pushed back
The FDA’s scheduled March 29 decision on Biogen Idec and Elan’s Tysabri will be delayed by as much as 90 days, the drug makers said this week.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.